Vanguard Group Inc. Has $590.91 Million Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Vanguard Group Inc. boosted its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 1.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 6,774,884 shares of the biotechnology company's stock after buying an additional 91,450 shares during the quarter. Vanguard Group Inc. owned approximately 10.66% of Blueprint Medicines worth $590,905,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Quarry LP acquired a new stake in shares of Blueprint Medicines in the third quarter valued at approximately $32,000. R Squared Ltd bought a new position in Blueprint Medicines in the fourth quarter valued at $51,000. Asset Management One Co. Ltd. acquired a new stake in Blueprint Medicines in the 4th quarter valued at $88,000. Van ECK Associates Corp lifted its position in Blueprint Medicines by 48.2% during the 4th quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company's stock worth $97,000 after buying an additional 363 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of Blueprint Medicines during the 3rd quarter worth about $108,000.

Analyst Upgrades and Downgrades

BPMC has been the topic of several analyst reports. Wedbush reiterated an "outperform" rating and set a $128.00 target price on shares of Blueprint Medicines in a report on Friday, February 28th. Jefferies Financial Group started coverage on Blueprint Medicines in a research note on Monday, March 17th. They set a "buy" rating and a $135.00 price objective on the stock. Scotiabank began coverage on shares of Blueprint Medicines in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $150.00 target price for the company. Stephens restated an "overweight" rating and set a $140.00 target price on shares of Blueprint Medicines in a report on Thursday, January 2nd. Finally, JMP Securities reiterated a "market outperform" rating and issued a $125.00 price target on shares of Blueprint Medicines in a research note on Friday, February 14th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Blueprint Medicines has an average rating of "Moderate Buy" and an average target price of $124.95.

Remove Ads

Blueprint Medicines Price Performance

Shares of Blueprint Medicines stock traded down $5.43 on Friday, reaching $81.68. 1,492,586 shares of the stock were exchanged, compared to its average volume of 742,386. The firm's 50 day moving average is $95.52 and its 200-day moving average is $93.99. The firm has a market cap of $5.22 billion, a PE ratio of -75.63 and a beta of 0.75. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. Blueprint Medicines Co. has a one year low of $80.08 and a one year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. As a group, analysts anticipate that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Insider Activity

In other Blueprint Medicines news, CEO Kate Haviland sold 1,446 shares of the company's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total value of $159,407.04. Following the completion of the transaction, the chief executive officer now owns 149,378 shares of the company's stock, valued at $16,467,430.72. This represents a 0.96 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jeffrey W. Albers sold 15,161 shares of Blueprint Medicines stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $109.53, for a total value of $1,660,584.33. Following the sale, the director now directly owns 152,396 shares in the company, valued at $16,691,933.88. The trade was a 9.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 31,608 shares of company stock worth $3,319,587. Corporate insiders own 4.21% of the company's stock.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.